BTAI

BioXcel Therapeutics Inc. is an innovative clinical-phase biopharmaceutical company located in New Haven, Connecticut, that leverages artificial intelligence to enhance drug discovery and development, particularly within neuroscience and immuno-oncology. The company is advancing a robust pipeline of therapies aimed at addressing critical unmet medical needs, underscoring its dedication to enhancing patient outcomes through groundbreaking treatments. By fusing cutting-edge AI capabilities with deep scientific knowledge, BioXcel is uniquely positioned to lead transformative changes in the healthcare industry, offering compelling opportunities for institutional investors seeking to engage in the biopharmaceutical sector.